Abstract
Fibromyalgia syndrome (FMS) is an under-diagnosed disorder of unknown aetiology, characterized by chronic widespread muscular pain, often accompanied by somatic and psychological symptoms. Several studies have described the impact of FMS on patients’ functionality, disability and quality of life. Other studies have reported on the burden to patients, healthcare payers and society. This review brings the existing evidence together and concludes that the patient burden of fibromyalgia is very high in comparison with many other conditions. The burden to healthcare payers and society is important as well, and can be mostly explained by factors not directly related to the treatment of FMS. Data suggest that the cost before diagnosis may even be higher than the cost after diagnosis. It is very likely that the combination of symptoms not only complicates the recognition and treatment of FMS, but also magnifies the burden of FMS.
Despite the complex and controversial construct of this syndrome, the results in terms of patient, healthcare payer and societal burden are quite consistent.
Similar content being viewed by others
References
Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008; 67 (4): 536–41
Reich JW, Johnson LM, Zautra AJ, et al. Uncertainty of illness relationships with mental health and coping processes in fibromyalgia patients. J Behav Med 2006; 29 (4): 307–16
Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. J Rheumatol 2005; 32 (11): 2270–7
Prodinger B, Cieza A, Williams DA, et al. Measuring health in patients with fibromyalgia: content comparison of questionnaires based on the International Classification of Functioning, Disability and Health. Arthritis Rheum 2008; 59 (5): 650–8
Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33 (2): 160–72
Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38 (1): 19–28
White KP, Speechley M, Harth M, et al. The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 1999; 26 (7): 1570–6
Carmona L, Ballina J, Gabriel R, et al. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 2001; 60: 1040–5
Salaffi F, De Angelis R, Grassi W, et al. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I: the MAPPING study. Clin Exp Rheumatol 2005; 23 (6): 819–28
Branco JC, Bannwarth B, Failde I, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum. Epub 2009 Feb 26
Zijlstra TR, Braakman-Jansen LM, Taal E, et al. Cost-effectiveness of spa treatment for fibromyalgia: general health improvement is not for free. Rheumatology (Oxford) 2007; 46 (9): 1454–9
Blotman F, Thomas E, Myon E, et al. Awareness and knowledge of fibromyalgia among French rheumatologists and general practitioners. Clin Exp Rheum 2005; 23: 697–700
Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007; 8: 27
Tüzün EH, Albayrak G, Eker L, et al. A comparison study of quality of life in women with fibromyalgia and myofascial pain syndrome. Disabil Rehabil 2004; 26 (4): 198–202
Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007 Apr 10; 68 (15): 1178–82
Theadom A, Cropley M, Humphrey KL. Exploring the role of sleep and coping in quality of life in fibromyalgia. J Psychosom Res 2007; 62 (2): 145–51
Arnould B, Benmedjahed K, Barnes N, et al. Qualitative steps for the development of a questionnaire assessing the burden of fibromyalgia on patients’ daily lives [PMS60 poster]. ISPOR 11th Annual European Congress; 2008 Nov 8–11; Athens
Offenbächer M, Cieza A, Brockow T, et al. Are the contents of treatment outcomes in fibromyalgia trials represented in the International Classification of Functioning, Disability, and Health. Clin J Pain 2007; 23 (8): 691–701
Kurtze N, Gundersen KT, Svebak S. The impact of perceived physical dysfunction, health habits and affective symptoms on employment status among fibromyalgia support group members. J Musculoskeletal Pain 2001; 9 (2): 39–53
Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991; 18: 728–33
White KP, Speechley M, Harth M, et al. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario: the London Fibromyalgia Epidemiology Study. Arthritis Rheum 1999; 42 (1): 76–83
White KP, Speechley M, Harth M, et al. The London Fibromyalgia Epidemiology Study: comparing the demographic and clinical characteristics in 100 random community cases of fibromyalgia versus controls. J Rheumatol 1999 Jul; 26 (7): 1577–85
Nicassio PM, Moxham EG, Schuman CE, et al. The contribution of pain, reported sleep quality, and depressive symptoms to fatigue in fibromyalgia. Pain 2002; 100 (3): 271–9
Henriksson CM, Liedberg GM, Gerdle B. Women with fibromyalgia: work and rehabilitation. Disabil Rehabil 2005 Jun 17; 27 (12): 685–94
Henriksson C, Liedberg G. Factors of importance for work disability in women with fibromyalgia. J Rheumatol 2000; 27 (5): 1271–6
Burckhardt CS, Clark SR, O’Reilly CA, et al. Pain-coping strategies of women with fibromyalgia: relationship to pain, fatigue, and quality of life. J Muscoskel Pain 1997; 5 (3): 5–21
Al-Allaf AW. Work disability and health system utilization in patients with fibromyalgia syndrome. J Clin Rheumatol 2007; 13 (4): 199–201
Assefi NP, Coy TV, Uslan D, et al. Financial, occupational, and personal consequences of disability in patients with chronic fatigue syndrome and fibromyalgia compared to other fatiguing conditions. J Rheumatol 2003; 30 (4): 804–8
White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008; 50 (1): 13–24
Evans CJ, Parthan A, Le K. Economic and humanistic burden of fibromyalgia in the USA. Expert Rev of Pharmacoecon and Outcomes Res 2006; 6 (3): 303–14
Kivimäki M, Leino-Arjas P, Kaila-Kangas L, et al. Increased absence due to sickness among employees with fibromyalgia. Ann Rheum Dis 2007; 66 (1): 65–9
Moldofsky H, Boussetta S, Le Lay K, et al. Career interruptions and sick leaves among fibromyalgia patient [THU0387 poster]. Paris: European League Against Rheumatology EULAR 2008 Jun: 11–4
Verbunt JA, Pernot DH, Smeets RJ. Disability and quality of life in patients with fibromyalgia. Health Qual Life Outcomes 2008; 6: 8
Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol 2004; 31 (4): 695–700
Yilmaz F, Sahin F, Ergoz E, et al. Quality of life assessments with SF 36 in different musculoskeletal diseases. Clin Rheumatol 2008; 27 (3): 327–32
Angst F, Verra ML, Lehmann S, et al. Responsiveness of five condition-specific and generic outcome assessment instruments for chronic pain. BMC Med Res Methodol 2008; 8: 26
Birtane M, Uzunca K, Taştekin N, et al. The evaluation of quality of life in fibromyalgia syndrome: a comparison with rheumatoid arthritis by using SF-36 Health Survey. Clin Rheumatol 2007; 26 (5): 679–84
Neumann L, Sukenik S, Bolotin A, et al. The effect of balneotherapy at the Dead Sea on the quality of life of patients with fibromyalgia syndrome. Clin Rheumatol 2001; 20 (1): 15–9
Pagano T, Matsutani LA, Ferreira EA, et al. Assessment of anxiety and quality of life in fibromyalgia patients. Sao Paulo Med J 2004; 122 (6): 252–8
Hoffman DL, Dukes EM. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract 2008 Jan; 62 (1): 115–26
Gusi N, Tomas-Carus P. Cost-utility of an 8-month aquatic training for women with fibromyalgia: a randomized controlled trial [abstract]. Arthritis Res Ther 2008; 10 (1): R24
Couto CI, Natour J, Carvalho AB. Fibromyalgia: its prevalence and impact on the quality of life on a hemodialyzed population. Hemodial Int 2008; 12 (1): 66–72
Löfgren M, Ekholm J, Ohman A. ‘A constant struggle’: successful strategies of women in work despite fibromyalgia. Disability Rehabil 2006; 28 (7): 447–55
Boonen A, van den Heuvel R, van Tubergen A, et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis 2005; 64 (3): 396–402
Maugars Y, Lamotte M, Devos C, et al. Fibromyalgia: the avoided cost of the non-diagnosed patient in France [THU0386 poster]. Paris: European League Against Rheumatology EULAR, 2008 Jun: 11–4
Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997; 40 (9): 1560–70
Robinson RL, Birnbaum HG, Morley MA, et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003; 30 (6): 1318–25
Robinson RL, Birnbaum HG, Morley MA, et al. Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently. J Rheumatol 2004; 31 (8): 1621–9
Berger A, Dukes E, Martin S, et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007; 61 (9): 1498–508
Penrod JR, Bernatsky S, Adam V, et al. Health services costs and their determinants in women with fibromyalgia. J Rheumatol 2004; 31 (7): 1391–8
Annemans L, Wessely S, Spaepen E, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum 2008; 58 (3): 895–902
Hughes G, Martinez C, Myon E, et al. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. Arthritis Rheum 2006; 54 (1): 177–83
Le Page JA, Iverson GL, Collins P. The impact of judges’ perceptions of credibility in fibromyalgia claims. Int J Law Psychiatry 2008; 31 (1): 30–40
Acknowledgements
This work was supported by the Public Health, Quality of Life, Health Economics Department of Pierre Fabre Laboratories by way of an unrestricted grant to Lieven Annemans. Charles Taïeb and Katell Le Lay are employees of Pierre Fabre and as such are eligible for stock options in the company. Pierre Fabre Laboratories market a product for the management of fibromyalgia.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Annemans, L., Le Lay, K. & Taïeb, C. Societal and Patient Burden of Fibromyalgia Syndrome. Pharmacoeconomics 27, 547–559 (2009). https://doi.org/10.2165/11313650-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11313650-000000000-00000